Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
2181-2200 of 2,251 trials

Head and Neck Cancer: New Treatment Approach with Pembrolizumab

We are studying a new sequence of treatments for patients with recurrent head and neck cancer to see if it improves survival compared to standard therapies. We will also evaluate how well patients tolerate the treatments and their quality of life.

Recurrent Head and Neck Squamous Cell Carcinoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Recovery After Gallbladder Surgery: Esmolol vs. Sufentanil

We are comparing two medications to see which one helps patients recover more comfortably after laparoscopic gallbladder surgery. This study aims to improve patient comfort during the recovery process.

Laparoscopic Gallbladder Removal1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal MedicineOrthopedics and TraumatologyOtolaryngology

Metastatic Colorectal Cancer: RAXO Trial

We are studying how metastatic colorectal cancer behaves and the effectiveness of different treatments in patients. This research aims to improve surgical options and overall patient outcomes.

Advanced Colorectal Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncology

Breast Cancer: Typology-based Coaching with Ribociclib

We are studying whether personalized coaching and education can help patients with HR+ HER2- early breast cancer stay on their ribociclib treatment. This may improve their treatment experience and overall health outcomes.

Hormone Receptor Positive Breast CancerBreast Cancer>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOncology

Scabies Treatment Comparison: Permethrin vs. Ivermectin

We are comparing the effectiveness of topical permethrin, oral ivermectin, and their combination for treating scabies. The goal is to find out which treatment works best and is safest for patients.

Scabies≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesDermatologyInfectious Diseases

Heart Patients: Reduced Dose of Prasugrel

We are studying whether a lower dose of prasugrel is safe and effective for patients after heart procedures. The trial also looks at how well patients stick to this treatment compared to the usual approach.

Acute and Chronic Coronary SyndromeMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Immune Thrombocytopenia: NVG-2089 Treatment Study

We are testing a new intravenous treatment, NVG-2089, for individuals with Immune Thrombocytopenia. The study aims to evaluate its safety and how well it works in increasing platelet counts.

Immune Thrombocytopenia (ITP)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementHematology

Onychomycosis: DexULac® Treatment Study

We are studying how well DexULac® works for treating nail fungal infections and its impact on patients' quality of life. This trial will help us understand the effectiveness and safety of this treatment over time.

Nail Fungus (Onychomycosis)1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesDermatologyInfectious Diseases

Head and Neck Cancer: NBTXR3 Treatment Study

We are studying a new treatment involving NBTXR3 with or without cetuximab for elderly patients with locally advanced head and neck cancer. The goal is to see if this approach improves survival compared to standard radiotherapy.

Head and Neck Cancer>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Solid Tumors: EIK1004 Treatment Study

We are testing a new treatment called EIK1004 for people with advanced solid tumors to see how safe it is and if it may help reduce tumor activity. This study will help us understand the best dose and its effects.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Cemiplimab for Advanced Adrenocortical Cancer

We are studying whether cemiplimab can help patients with advanced adrenocortical cancer maintain their health after initial treatment. This trial focuses on those who have not experienced disease progression.

Adrenocortical Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Kidney Transplant: Reduced Immunosuppression for Older Adults

We are studying whether a lower dose of immunosuppressive medication is as effective and safe as the standard dose for older adults after kidney transplantation. This may help improve their overall health and quality of life.

End-stage Renal Disease1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Glioblastoma: Intraoperative Photodynamic Therapy with Pentalafen®

We are studying a new light-based treatment for adults with grade IV glioblastoma during surgery. The goal is to evaluate its safety and how well it works in reducing tumor response.

Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Hidradenitis Suppurativa: Sonelokimab Study

We are studying the long-term safety and effectiveness of sonelokimab for people with moderate to severe hidradenitis suppurativa. This research aims to improve symptoms and quality of life for participants.

Hidradenitis Suppurativa>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatology

Advanced Breast Cancer: PF-07248144 with Fulvestrant

We are studying a new treatment combining PF-07248144 and fulvestrant for adults with hormone receptor-positive, HER2-negative advanced breast cancer. This trial aims to see if it helps patients whose cancer has progressed after prior therapy.

Hormone Receptor-Positive, HER2-Negative Breast CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Breast Cancer: Patritumab Deruxtecan vs. Standard Treatment

We are studying a new medication for patients with hormone receptor-positive, HER2-negative advanced breast cancer. The goal is to see if it works better than the current treatment options.

Hormone Receptor Positive Breast Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGynecology and ObstetricsOncology

ELA026 for Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

We are studying the effects of ELA026 on survival in patients with sHLH triggered by lymphoma. This trial will help us understand how well this treatment works and its safety.

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)3-6 monthsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyInfectious Diseases

Dengue Vaccine Qdenga: Antibody Response Study

We are examining how the Qdenga vaccine affects antibody levels for other flavivirus infections in Swedish travelers. This study aims to see if vaccination leads to higher antibody levels that could interfere with diagnostic tests.

Healthy Participants3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesAllergologyHematologyInfectious Diseases

GSK5764227 for Advanced Gastrointestinal Tumors

We are studying a new treatment for patients with advanced unresectable or metastatic gastrointestinal tumors that have been previously treated. The trial aims to evaluate how well this treatment works and its safety.

Gastrointestinal Neoplasms6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboCost ReimbursementPartially RemoteGastroenterologyOncology

Nasopharyngeal Carcinoma: Imaging Study with [68Ga]Ga-DOTA-TOC

We are exploring a new imaging method to assess tumors in patients with EBV-related nasopharyngeal carcinoma. This study aims to improve treatment choices by understanding how the tumor responds to therapy.

Nasopharyngeal Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology